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Nonalcoholic fatty liver disease (NAFLD) now ranks as 
the most prevalent liver disease worldwide (1), but progres-
sion from its more indolent stage of nonalcoholic fatty liver 
(NAFL) to advanced stages of nonalcoholic steatohepatitis 
(NASH) is not well understood. The accumulation of neu-
tral lipids (principally triglycerides, TGs) within hepatocel-
lular lipid droplets (LDs) in obese subjects with NAFL 
largely reflects increased de novo lipogenesis. In addition, 
the excessive hepatic TG burden also promotes augmented 
VLDL secretion and leads to systemic hypertriglyceridemia. 
The progressive forms of liver injury with NASH are charac-
terized by lipotoxicity, hepatic inflammation, and fibrosis, 
but the mechanisms linking alterations in circulating tri-
glycerides and LD turnover to NASH remain obscure.
In this issue of the Journal of Lipid Research, Dongiovanni 
et al. propose that upregulation of the type I membrane-
bound pro-protein convertase subtilisin/kexin type 7 
(PCSK7) mechanistically links hypertriglyceridemia with 
hepatic inflammation via hepatic iron dysmetabolism. Dis-
covered in 1996 as one of nine secretory pro-protein con-
vertase family members responsible for the intracellular 
cleavage of pro-proteins, PCSK7 is a relatively conserved 
protein with nearly ubiquitous tissue distribution (2). Ge-
nome-wide association study data have demonstrated an 
association between the PCSK7 rs236918 C risk allele, sol-
uble transferrin receptor (3), liver cirrhosis in hemo-
chromatosis patients (4), and hypertriglyceridemia (5, 6). 
Because of these prior genetic associations and evidence 
that excessive hepatic iron accumulation predicts hepatic 
inflammation and fibrosis in NASH (7, 8), Dongiovanni 
et al. hypothesized that PCSK7 may be “the bridge that 
connects lipid dysregulation with liver injury in NAFLD”.
The investigators used three genetic cohorts to explore 
the relationship between the PCSK7 rs236918 C risk allele, 
iron dysmetabolism, liver injury, and hypertriglyceridemia: 
1) the Liver Biopsy Cohort (LBC), a group of European 
adults from Italian and Finnish referral centers who were 
enrolled after liver biopsy confirmed NASH diagnosis; 2) 
the UK Biobank (UKBBC), a genetic dataset of UK partici-
pants; and 3) the Dallas Heart Study (DHS), a US-based, 
multi-ethnic cohort of participants who reside in Dallas 
County, Texas. The effect of the PCSK7 rs236918 C risk 
variant on liver injury was estimated by measuring the as-
sociation of the variant with either histologic or surrogate 
markers of steatosis, hepatic inflammation, and fibrosis in 
the three cohorts. In the LBC, there was an association 
between the PCSK7 rs236918 C risk allele, abnormal he-
patic transaminases, and histologic lobular inflammation, 
although not with the sine qua non NASH histologic find-
ings of hepatocellular ballooning or fibrosis. Perhaps 
counterintuitively, there was no association with steatosis 
in either the LBC or DHS cohorts except in LBC subjects 
considered high risk for progressive NAFLD or who car-
ried the previously validated NASH genetic risk allele 
I148M PNPLA3 variant. Phenotypically, the PCSK7 risk 
variant associated with liver failure and cirrhosis in the 
UKBBC dataset; however, there was no stratification by 
PNPLA3 status in this cohort.
Dongiovanni et al. convincingly demonstrate that PCSK7 
expression contributes to the TG phenotype, showing a 
positive association of the rs236918 C risk variant with hy-
pertriglyceridemia in the LKB dataset. In addition, they 
observed an association of another low-frequency mis-
sense mutation in PCSK7 (rs142953140) with elevated cir-
culating TGs in the DHS cohort and association of a 
low-frequency PCSK7 missense mutation (rs142953140) 
found in African Americans with lower TGs. Finally, in the 
UKBB, the PCSK7 risk variant was associated with cardio-
vascular disease and hypercholesterolemia, perhaps re-
flecting the previously established relationship between 
hypertriglyceridemia and propensity for development of 
atherogenic, lower density LDL particles (9).
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Using a combination of bioinformatics and gene tran-
script expression data, the authors propose that the PCSK7 
risk variant is a gain-of-function mutation that increases 
hepatic PCSK7 protein expression (and secretion) by mod-
ulating expression of an 83 bp regulatory segment of long 
noncoding RNA (so-called “intra-PCSK7” lnc RNA). In sup-
port of this hypothesis, they observed increased hepatic 
expression of intra-PCSK7 in severely obese (a NAFLD-
enriched population) carriers of the PCSK7 rs236918 C 
allele. Moreover, both hepatic and circulating PCSK7 pro-
tein expression were increased in risk allele carriers, the 
latter of which correlated positively with circulating TG 
levels in NAFLD patients.
A mechanistic examination of the authors’ hypothesis 
in PCSK7 haploinsufficient HepG2 cells revealed impaired 
PCSK7 secretion, a relative reduction in the de novo lipo-
genic genes FAS and SREBP1, and reduced FA-induced 
neutral lipid accumulation compared with wild-type 
HepG2 cells. Haploinsufficiency also resulted in the down-
regulation of the inflammatory gene TNFa and of the fibro-
genic gene TGFb and its downstream effectors SMAD2/3 
and SMAD4.
Although the in vitro data are bolstered by the finding 
in severely obese patients that hepatic PCSK7 expression 
correlates with FAS, TGFb, actin, and Col1A1 gene expres-
sion, the authors’ transcriptome pathway analysis adds a 
level of complexity to the biology of PCSK7. Specifically, 
they demonstrate coexpression of PCSK7 with genes in-
volved in inflammation, epithelial mesenchymal transi-
tion, and mitosis but unlike the in vitro data, they found 
an inverse correlation with pathways involved in adipogen-
esis and FA metabolism. Those findings imply that the ef-
fects of PCSK7 on FA utilization may either be in promoting 
oxidation (as evidenced by the positive correlation with 
the b oxidative genes PPARa and CPT1 in HepG2 PCSK7 
haploinsufficient cells and severely obese subjects) or in 
downregulating b oxidation as demonstrated by the in-
verse correlation of PCSK7 with oxidative phosphorylation 
pathways in transcriptome analysis. Understanding the 
relationship of PCSK7 with hepatic fat oxidation is critical 
as strategies that target PCSK7 could either improve or 
worsen the NAFLD phenotype.
Dongiovanni et al. have built a few more beams to “span 
the tide” (10) in NAFLD pathogenesis. What remains is to 
define in greater detail the link between dysregulated he-
patocellular LD formation and turnover and systemic hy-
pertriglyceridemia and the mechanisms by which PCSK7 
modulates these pathways. One possibility, given the ubiq-
uitous distribution of PCSK7, could include the role of al-
tered intestinal chylomicron assembly and secretion. The 
emergence of genetically modified in vivo models would 
enable these physiologic questions to be answered. Never-
theless, Dongiovanni and colleagues have established an 
approach to move beyond genome-wide association study 
data to more mechanistic underpinnings of NASH devel-
opment and provide strong evidence that PCSK7 should 
be added to the growing list of genetic modifiers at the 
interface of NAFL and NASH phenotypes (11).
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